Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Thermo Fisher Scientific Inc., profitability ratios (quarterly data)

Microsoft Excel
Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).


The profitability profile exhibits two distinct phases: a period of significant contraction from early 2022 through mid-2023, followed by a period of gradual recovery and stabilization extending through March 2026.

Profit Margin Analysis
Gross profit margin experienced a sharp decline from a peak of 48.37% in April 2022 to a trough of 39.75% in July 2023. Following this low point, a consistent recovery trend is observed, with the margin climbing to 41.28% by December 2024 and remaining relatively stable around 40.78% to 41.27% through the end of the period.
Operating profit margin mirrored the gross margin trajectory, falling from 23.83% in April 2022 to a low of 15.42% in July 2023. A steady recovery followed, with the margin expanding to 17.46% by March 2026, suggesting improvements in operational efficiency and cost management during the latter half of the observed timeframe.
Net profit margin followed a similar pattern, decreasing from 18.49% in April 2022 to 13.14% in July 2023. This metric then trended upward, reaching 15.15% by March 2026, though it remained below the initial 2022 levels.
Return Metrics and Asset Efficiency
Return on equity (ROE) showed a sustained downward trend from 18.56% in April 2022 to a low of 12.52% in September 2024. While a slight recovery to 13.19% is noted by March 2026, the ROE remained significantly lower than its starting position, indicating a reduction in the return generated on shareholder investments.
Return on assets (ROA) declined from 8.20% in April 2022 to a low of 6.08% in July 2023. From mid-2023 onward, ROA entered a stabilization phase, fluctuating within a narrow range between 6.05% and 6.58%, signaling a plateau in the efficiency of asset utilization.

Overall, while profit margins have demonstrated resilience and a clear recovery trend since mid-2023, the return metrics (ROE and ROA) have not returned to their early 2022 peaks, suggesting that the operational recovery has not yet fully translated back into historical levels of capital efficiency.


Return on Sales


Return on Investment


Gross Profit Margin

Thermo Fisher Scientific Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Gross profit
Revenues
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q1 2026 Calculation
Gross profit margin = 100 × (Gross profitQ1 2026 + Gross profitQ4 2025 + Gross profitQ3 2025 + Gross profitQ2 2025) ÷ (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The gross profit margin exhibits a distinct three-phase trajectory characterized by an initial sharp contraction, a period of gradual recovery, and a subsequent stabilization phase. Over the analyzed period, the margin transitioned from a peak of 48.37% to a trough of 39.75%, before establishing a new baseline in the 40-41% range.

Initial Margin Compression
A significant downward trend is observed between April 2022 and July 2023. During this window, the gross profit margin declined consistently from 48.37% to 39.75%. This contraction occurred despite revenues remaining relatively robust, indicating that the cost of goods sold increased at a faster rate than revenue growth or that there was a shift in product mix toward lower-margin offerings.
Recovery and Incremental Improvement
Following the trough in July 2023, a period of gradual margin expansion is evident. From September 2023 through December 2024, the gross profit margin rose steadily from 39.87% to a peak of 41.34%. This suggests a successful implementation of cost-containment measures or an increase in pricing power that allowed the organization to recover a portion of the previously lost profitability.
Stabilization Phase
From March 2025 through March 2026, the gross profit margin entered a state of equilibrium, fluctuating narrowly between 40.78% and 41.27%. This indicates that the profitability levels reached in late 2024 became the new operational norm, with the margin remaining resilient despite variations in quarterly revenue.
Revenue and Gross Profit Correlation
Revenue showed moderate volatility, reaching a high of 12,215 million US dollars in December 2025. While gross profit followed the general direction of revenue, the discrepancy in the growth rates during 2022 highlights the initial margin erosion. By the final periods of the analysis, the relationship between revenue and gross profit became more linear, confirming the stabilization of the margin at approximately 41%.

Operating Profit Margin

Thermo Fisher Scientific Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Operating income
Revenues
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q1 2026 Calculation
Operating profit margin = 100 × (Operating incomeQ1 2026 + Operating incomeQ4 2025 + Operating incomeQ3 2025 + Operating incomeQ2 2025) ÷ (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The operational profitability of the organization underwent a significant transition between April 2022 and March 2026, characterized by an initial steep contraction followed by a steady, multi-quarter recovery phase.

Margin Contraction Period
A pronounced downward trend in the operating profit margin is observed from April 2, 2022, to July 1, 2023. During this interval, the margin declined from a peak of 23.83% to its lowest point of 15.42%. This contraction was driven by a substantial decrease in operating income, which fell from 2,821 million USD to 1,578 million USD, while revenues remained relatively stable, fluctuating between 10.6 billion USD and 11.8 billion USD.
Recovery and Stabilization Phase
Following the trough in July 2023, a consistent upward trajectory in profitability is evident. The operating profit margin climbed steadily, reaching 17.46% by March 28, 2026. A period of relative stability is noted from June 2024 through March 2026, where the margin consistently maintained a range between 16.93% and 17.46%.
Revenue and Operating Income Correlation
While revenues showed periodic fluctuations—peaking at 12,215 million USD in December 2024—the recovery in the operating profit margin suggests a decoupling of profitability from pure volume growth. The gradual increase in margin from 15.42% back toward 17.46% indicates successful operational adjustments or cost-management initiatives implemented after the mid-2023 low.

Net Profit Margin

Thermo Fisher Scientific Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Net income attributable to Thermo Fisher Scientific Inc.
Revenues
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q1 2026 Calculation
Net profit margin = 100 × (Net income attributable to Thermo Fisher Scientific Inc.Q1 2026 + Net income attributable to Thermo Fisher Scientific Inc.Q4 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025) ÷ (RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


An analysis of the quarterly financial results reveals a distinct three-phase trend in profitability, characterized by an initial contraction, a period of recovery, and a final phase of stabilization.

Net Profit Margin Trajectory
A significant downward trend is observed from April 2022 to July 2023, during which the net profit margin declined from a peak of 18.49% to a trough of 13.14%. This represents a contraction of 5.35 percentage points over fifteen months. Following this low point, a consistent recovery phase occurred, with margins climbing steadily to reach 15.23% by June 2025.
Revenue and Income Correlation
The volatility in profit margins corresponds with fluctuations in both revenue and net income. A period of decreased efficiency was evident between April 2023 and March 2024, where revenues hit a low of 10.345 billion USD and net income dropped to 1.289 billion USD. The subsequent recovery in profitability coincided with an expansion in top-line growth, culminating in a revenue peak of 12.215 billion USD in December 2025.
Profitability Stabilization
The final period of the analysis, spanning from June 2025 to March 2026, indicates a stabilization of net profit margins. During these three quarters, the margin remained highly consistent, fluctuating within a narrow range between 15.02% and 15.15%. This suggests a normalization of operating costs and a steady state of profitability relative to revenue generation.

Return on Equity (ROE)

Thermo Fisher Scientific Inc., ROE calculation (quarterly data)

Microsoft Excel
Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Net income attributable to Thermo Fisher Scientific Inc.
Total Thermo Fisher Scientific Inc. shareholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q1 2026 Calculation
ROE = 100 × (Net income attributable to Thermo Fisher Scientific Inc.Q1 2026 + Net income attributable to Thermo Fisher Scientific Inc.Q4 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025) ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Equity (ROE) exhibits a pronounced downward trajectory from the beginning of the analyzed period, transitioning from a peak of 18.56% in April 2022 to a stabilized range between 12.5% and 13.2% throughout 2024 and 2025. This contraction indicates a decrease in the efficiency of generating profits relative to the shareholders' equity base.

Return on Equity Trend
A significant decline is observed between April 2022 and July 2023, where the ROE fell from 18.56% to 13.08%. Following this contraction, the ratio entered a phase of relative stabilization, fluctuating marginally between a low of 12.52% in September 2024 and a high of 13.26% in March 2024, ending the period at 13.19% in March 2026.
Equity Base Expansion
Total shareholders' equity grew steadily from 40,956 million US$ in April 2022 to 51,934 million US$ by March 2026. The consistent expansion of the equity base has exerted downward pressure on the ROE, as the increase in the equity denominator outpaced the growth in net income over the medium term.
Net Income Performance
Net income attributable to the company demonstrated notable volatility, starting at 2,215 million US$ in April 2022 and reaching a low of 1,289 million US$ in April 2023. Although a recovery trend is evident toward the end of 2025, with a peak of 1,964 million US$ in December 2025, the earnings levels remained generally lower than the initial 2022 peaks, further contributing to the compression of the ROE.

Return on Assets (ROA)

Thermo Fisher Scientific Inc., ROA calculation (quarterly data)

Microsoft Excel
Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Net income attributable to Thermo Fisher Scientific Inc.
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q1 2026 Calculation
ROA = 100 × (Net income attributable to Thermo Fisher Scientific Inc.Q1 2026 + Net income attributable to Thermo Fisher Scientific Inc.Q4 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of profitability indicators reveals a general downward trajectory in the Return on Assets (ROA) over the observed period, transitioning from a peak of 8.21% in July 2022 to 6.05% by March 2026. This progression is characterized by an initial sharp contraction followed by a prolonged period of stabilization and a eventual slight decline as the asset base expanded.

Return on Assets Trend
A significant decline in ROA is observed between April 2022 and July 2023, where the ratio fell from 8.20% to 6.08%. This compression was primarily driven by a substantial reduction in quarterly net income, which decreased from $2,215 million to $1,361 million during this timeframe, while total assets remained relatively stable.
Asset Base Expansion
Total assets exhibited a consistent long-term upward trend, increasing from $92,747 million in April 2022 to $113,281 million by March 2026. This growth in the denominator of the ROA calculation has created a systemic headwind for profitability efficiency, requiring significantly higher net income levels to maintain previous ROA percentages.
Profitability Stabilization
Between July 2023 and March 2025, the ROA entered a stabilization phase, oscillating within a narrow range between 6.07% and 6.58%. During this period, net income showed moderate recovery, reaching $1,829 million in September 2024, which effectively offset the gradual increase in total assets and prevented further erosion of the ratio.
Recent Performance Divergence
In the final period from March 2025 to March 2026, a divergence is noted between asset growth and return efficiency. Despite a notable peak in net income of $1,964 million in December 2025, the rapid acceleration of total assets to $113,281 million resulted in a downward slide of the ROA, ending the period at 6.05%.